Our Company

At Sigilon, we are pioneering a new class of therapeutics and seeking to develop functional cures for patients with a wide range of chronic diseases. Our Shielded Living TherapeuticsTM platform combines advanced cell engineering with innovations in biocompatible materials, potentially enabling our product candidates to produce a wide range of therapeutic molecules that may be missing or deficient in the body, including proteins, antibodies and enzymes.

Our platform technology was inspired by more than a decade of work at MIT by our academic cofounders, Bob Langer and Dan Anderson, and supported by Flagship Pioneering’s strategic vision. Together, this work paved the way for us to build a diverse pipeline spanning rare blood, lysosomal storage, and endocrine diseases.

 

 

Our aspiration

From cell function to functional cure to create a world without chronic disease.

Our team

Leadership
  • Leadership
  • Board of Directors
  • Founders
  • Scientific Advisory Board
Rogerio Vivaldi, M.D., M.B.A
Rogerio Vivaldi, M.D., M.B.A President, Chief Executive Officer +
Leadership, Board of Directors

Rogerio Vivaldi Coelho, M.D., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018, and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme’s rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme’s Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro.

Devyn Smith, Ph.D.
Devyn Smith, Ph.D. Chief Operating Officer +
Leadership

Devyn Smith, Ph.D., has served as our Chief Operating Officer since 2017. Prior to joining Sigilon, Dr. Smith served in roles of increasing responsibility at Pfizer Inc. from 2009 until 2017, including Head of Business Operations & Strategy for Pfizer’s Medicinal Sciences Division of R&D. His responsibilities in this position included oversight of both the day-to-day business operations of the division and the development of implementable strategies. Before his time at Pfizer Inc., Dr. Smith was a principal for The Frankel Group LLC, a management consulting firm. Dr. Smith received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an M.S. in Biology from Idaho State University and a B.S. in Zoology from Brigham Young University.

Glenn Reicin, M.B.A.
Glenn Reicin, M.B.A. Chief Financial Officer +
Leadership

Glenn Reicin, M.B.A., has served as our Chief Financial Officer since 2019. Mr. Reicin is a biotechnology and medical technology executive with experience across finance, operations and investor relations. From 2013 until 2019, Mr. Reicin served as President of Greyrock Biomedical Advisors, Ltd., which provides a range of deal sourcing, valuation, due diligence and management consulting services for companies in the healthcare space. Mr. Reicin currently serves on the board of directors of Amplitude Healthcare Acquisition Corporation, a public specialty purpose acquisition company. Previously, he served as an Executive-in-Resident at Covidien Plc and Managing Director at Skyline Ventures Management LLC. At Skyline Ventures Management LLC, he served as an active board member at a number of biotech firms, including Novasys Medical Inc., a maker of minimally invasive treatments for female incontinence, SI-Bone Inc., a developer of a minimally invasive surgical treatment for sacroiliac joint disorders, and Spinal Motion, Inc., a developer of artificial disc implants to preserve motion at the treated spinal segment of the body. Mr. Reicin held various position of increasing responsibility at Morgan Stanley where he served as a Managing Director at Morgan Stanley where he headed their Healthcare Equity Research team. He started his career at Morgan Stanley where he became a Managing Director in equity research covering medical technology. His sell-side career spanned 18 years, including 15 years as a top-three ranked analyst and six consecutive years in the top spot. Mr. Reicin holds an M.B.A. from Harvard Business School and a B.A. from Brandeis University.

Anne Altmeyer, Ph.D., M.B.A, MPH
Anne Altmeyer, Ph.D., M.B.A, MPH Chief Business Officer +
Leadership

Anne Altmeyer, Ph.D., M.B.A, MPH, has served as our Chief Business Officer since 2019. Prior to joining Sigilon, Dr. Altmeyer served as the Chief Business Officer at Adicet Bio, Inc., from 2016 until 2019, where she oversaw corporate development, alliance management, project/supply relationship management and quality. Prior to joining Adicet Bio Inc., Dr. Altmeyer was Vice President Business Development & Licensing at Baxalta (acquired by Shire plc) from 2015 until 2016, where she focused on global transactions in different therapeutic areas, including oncology, hematology, and immunology. Before Baxalta, she worked at Novartis International AG for over a decade in positions of increasing responsibilities within business development and project leadership. Dr. Altmeyer previously served in various positions at Merck & Co. from 2000 until 2004. Dr. Altmeyer received her Ph.D. in molecular immunology from Strasbourg University in France. She then performed a postdoctoral fellowship at New York University School of Medicine and subsequently became a research associate at Cornell University Medical College. In addition to her scientific training, she also received an M.B.A. and MPH from Rutgers University and the University of Medicine and Dentistry, New Jersey, USA.

Hozefa Bandukwala, Ph.D.
Hozefa Bandukwala, Ph.D. Vice President, Platform Innovation +
Leadership

Hozefa Bandukwala, Ph.D., a trained immunologist, has spent his career pioneering the translation of advances in the emerging field of immunometabolism for novel drug development. Dr. Bandukwala has substantial industry experience in both big pharmaceutical and small biotechnology companies identifying novel targets for treatment of immunological diseases. Before Sigilon Therapeutics, Dr. Bandukwala served as Head of the Immunmetabolism Laboratory at Pfizer and Senior Director and Head of Discovery Biology at Rheos Medicines, where he led research efforts on manipulating immune cell metabolism for therapeutic applications in autoimmunity and immune-oncology. Dr. Bandukwala earned a B.S. in biotechnology from the Indian Institute of Technology, Bombay and then pursued a Ph.D. in immunology from University of Chicago, where his research focused on the regulation of Th2 responses by Fc receptor signaling on dendritic cells. Dr. Bandukwala’s postdoctoral fellowship at Harvard University focused on epigenetic and metabolic regulation of T cell functions. His research has resulted in several high-profile publications.

Deya Corzo, M.D.
Deya Corzo, M.D. Chief Medical Officer +
Leadership

Deya Corzo, M.D., has served as our Chief Medical Officer since 2018. Previously, Dr. Corzo served as Chief Medical Officer of Sojournix Inc., from 2017 until 2018, where she led a team responsible for IND/CTA regulatory filings in the United States and the United Kingdom, the execution of their first-in-human clinical trials in those geographies, and for building up the company’s clinical development group. Dr. Corzo previously served as SVP of R&D and Therapeutic Area Head for liver-amenable gene therapies at uniQure N.V. from 2014 until 2017, as Executive Medical Director at Celgene from 2012 until 2014, and various positions at Sanofi Genzyme from 2001 until 2008. Dr. Corzo is a faculty member of Harvard Medical School and a board-certified attending physician in Clinical Genetics at Boston Children’s Hospital. She completed a residency in Pediatrics at Maimonides Medical Center in Brooklyn, NY, a clinical fellowship in Genetics at Boston Children’s Hospital and a research fellowship in Immunogenetics at the Dana-Farber Cancer Institute. Dr. Corzo received her medical degree with a cum laude distinction from the Universidad Industrial de Santander in her native Colombia.

Susan Drapeau, Ph.D.
Susan Drapeau, Ph.D. Vice President, Head of Device and Delivery Engineering +
Leadership

Susan Drapeau, Ph.D., has over 20 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development. Prior to joining Sigilon, she served as the Senior Director of Business Development and Strategy at Vericel Corporation, where she evaluated new technologies and supported MACI and Epicel, two FDA approved autologous cellular therapies. Prior to Vericel, Dr. Drapeau spent 14 years at Medtronic Spine running part of the biologics product development organization as well as leading due diligence efforts in business development. While at Medtronic, her team launched five products, gained many 510(k) approvals, submitted several INDs and supported manufacturing, tech transfer, due diligence and intellectual property. Prior to Medtronic, Dr. Drapeau ran the bone product development team at Osiris Therapeutics, focusing on allogeneic cell therapies in combination with biomaterials. During her career Dr. Drapeau has worked in orthopedics, cardiac, burn, dental and pain therapies. In addition to industry experience, Dr. Drapeau serves as an advocate for the biomedical field currently as a Director and previously as the Industry Chair of the American Institute of Medical and Biological Engineering. She also serves on the Advisory Board for UCSF Tissue Engineering Consortium Grant. Dr. Drapeau holds B.S. degrees in chemical engineering and chemistry from Purdue University and a Ph.D. in chemical engineering from Rice University. She is an inventor on 60 patents and a co-author of 90 journal articles, book chapters and presentations.

Melodie Henderson, J.D.
Melodie Henderson, J.D. VP, IP Counsel +
Leadership

Melodie Henderson, J.D., is a registered U.S. patent attorney with over 20 years of legal, management and R&D experience with life science companies. Prior to joining Sigilon, Ms. Henderson was the first in-house IP counsel at Minerva Neurosciences. Previously, Ms. Henderson served as a Legal Director for 11 years at Schering Pough/Merck, where her responsibilities included building and managing the patent portfolio for several pre-clinical and clinical biologics programs as well as five marketed products. Ms. Henderson’s first in-house legal role was at Genaissance Pharmaceuticals, where she established the IP function and managed a team of patent professionals. Before going in-house, Ms. Henderson began her legal career as an associate attorney at two IP boutique law firms. Ms. Henderson holds a B.A. degree in biochemistry from the University of Kansas, an M.S. degree in biochemistry from St. Louis University and a J.D. from the University of Connecticut

Olivia G. Kelly, Ph.D.
Olivia G. Kelly, Ph.D. VP, Head of Islet Cell Therapy Research +
Leadership

Olivia G. Kelly, Ph.D., has over 13 years of experience in the biotechnology industry developing cell therapies. Prior to joining Sigilon, Dr. Kelly served as the Senior Director of Cell Biology at ViaCyte, a clinical stage company focused on developing stem cell-derived therapies for diabetes, where she led efforts in stem cell differentiation, assay development, quality control and tumorigenicity studies which supported multiple IND/CTA filings and achieved multiple research grant and licensing milestones. Dr. Kelly has coauthored a number of high-profile journal publications and is a co-inventor on multiple patents. Dr. Kelly earned a B.S. in Molecular Biology from the University of Texas at Austin and then pursued a Ph.D. in Biochemistry and Molecular Biology from Harvard University, where her research focused on molecular mechanisms of early embryonic patterning and pancreas development. Dr. Kelly’s postdoctoral fellowships at the University of California at Berkeley/San Francisco and Baylor College of Medicine focused on signaling mechanisms that regulate the development of various tissues and stem cell differentiation.

Matthew Kowalsky, J.D.
Matthew Kowalsky, J.D. Chief Legal Officer +
Leadership

Matthew Kowalsky, J.D., currently serves as our Chief Legal Officer. Prior to joining Sigilon, he served as Vice President of Legal and Corporate Secretary at Proteon Therapeutics, Inc. from 2016 to 2019. Prior to that, he served as Senior Corporate Counsel at Sanofi Genzyme from 2015 to 2016, supporting business development activities and marketed products for rare diseases. Mr. Kowalsky held the position of Associate General Counsel at Cubist Pharmaceuticals, Inc. from 2013 to 2015. He has also held similar roles at ARIAD Pharmaceuticals, Inc. and Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.). Mr. Kowalsky began his legal career in the corporate and intellectual property groups of Choate, Hall & Stewart LLP. He holds a B.A. from the University of Notre Dame and a J.D. from the Notre Dame Law School. Before attending law school, he served as a surface warfare officer in the U.S. Navy.

Elina Makino, Ph.D.
Elina Makino, Ph.D. VP, Rare Diseases +
Elina Makino, Ph.D. Leadership

Elina Makino, Ph.D., has substantial industry experience in small molecule and biologics R&D. Throughout her  25-year career she was working in academia and industry,  working in the field of drug discovery and developed life-saving therapies for Rare Disorders, Malignancies and Metabolic diseases. Before Sigilon, Dr. Makino held a leadership position at Sanofi, where she led  discovery of Venglustat, small molecular inhibitor of glucosylceramide synthase currently in clinical trials for Fabry, Gauche type 3, Parkinson and ADPKD. She was a Program Lead for MPSI  as well as Scientific Lead for several programs for various lysosomal storage disorders. Dr. Makino has numerous patents and publications to her name. She received her Ph.D. and post-doctoral training in biochemistry from the Weizmann Institute of Life science and Harvard Medical School.

David Peritt, Ph.D.
David Peritt, Ph.D. Chief Technology Officer +
Leadership

David Peritt, Ph.D., has served as our Chief Technology Officer since 2017. Prior to joining Sigilon, Dr. Peritt held various leadership positions including Program Lead for Cell and Gene Therapy at
Pfizer Inc. from 2016 until 2017 and Director, Biosimilars Biology at Pfizer Inc. from 2015 until 2016. Prior to Pfizer Inc., Dr. Peritt served in various roles at Hospira, Inc. from 2007 until 2015. Dr. Peritt has led research efforts at several divisions of Johnson & Johnson, including Centocor Biotech, Inc. and Therakos, Inc. and worked in governmental agencies such as the USDA, Walter Reed Army Medical Center and the Sharrett Cancer Institute. Dr. Peritt received his Ph.D. and post-doctoral training in immunology from the University of Pennsylvania and the Wistar Institute, respectively.

Josias Pontes, M.B.A.
Josias Pontes, M.B.A. VP, Head of Finance +
Leadership

Josias Pontes, M.B.A., brings over 25 years of finance and accounting experience to the company. Before joining Sigilon, he was Senior Director of Financial Planning and Analysis at Zafgen, Inc. Mr. Pontes’ career in the life science industry began at Genzyme (now Sanofi Genzyme) where his most recent position was as Senior Director of Finance, Rare Diseases. At Genzyme he spent over a decade in different positions, leading the finance and accounting functions to support the significant and rapid growth of the rare diseases business in Latin America and in U.S. Mr. Pontes had multiple roles at Genzyme, working as Head of Finance and Controller at a country level in Brazil, Chile and Venezuela then at a regional level as Senior Director of Finance, Regional Controller Latin America. Mr. Pontes has also held a senior financial position at Juniper Pharmaceuticals. He has also held progressive finance positions in manufacturing and commercial settings in different industries such as air conditioning and automotive among others. Mr. Pontes started his accounting career at a subsidiary of United Steel Corporation and had about 8 years of accounting experience prior to joining Price Waterhouse (now PricewaterhouseCoopers) and earned a CPA in the state of Sao Paulo, Brazil. He holds a B.A. from the FECAP University in Sao Paulo and an M.B.A. from Ohio University.

Martha Rook, Ph.D.
Martha Rook, Ph.D. SVP, Head of Manufacturing +
Leadership

Martha Rook, Ph.D., has joined Sigilon in 2018 and has served as our Senior Vice President, Head of CMC and Analytics since 2020. Dr. Rook previously served as our Senior Vice President, Head of Manufacturing from 2018 until 2020. Prior to joining Sigilon, Dr. Rook was VP and Head of the Gene Editing & Novel Modalities Business of MilliporeSigma from 2016 until 2018. There she led a team developing and providing tools and services for cell and gene therapies from discovery to manufacturing. Dr. Rook also previously held a variety of senior roles at MilliporeSigma from 2005 through 2016, including Head of Novel Therapies, Director of Stem Cell Bioprocessing and Head of Upstream and Sensor Technologies. Prior to joining MilliporeSigma, Dr. Rook worked in the clinical diagnostics field at Quest Diagnostics and Variagenics. Dr. Rook received her Ph.D. in biochemistry from MIT and holds a B.S. in chemistry from Texas A&M University. She pursued post-doctoral studies in neuroscience as a Lefler Fellow at Harvard Medical School’s Center for Neurologic Diseases.

Vanya Sagar, M.P.A.
Vanya Sagar, M.P.A. Chief Human Resources Officer +
Leadership

Vanya Sagar, M.P.A. joined Sigilon in 2018 and has served as our Chief Human Resources Officer since June 2020. Ms. Sagar previously served as Sigilon’s SVP, Head of Human Resources and VP, Head of HumanResources. Prior to joining Sigilon, Ms. Sagar served in roles of increasing responsibility at Biogen Inc. from 2015 until 2018, including Human Resources Business Partner for the Research and Early Development organization at Biogen Inc. and prior to that, for the global Finance organization. Before her time at Biogen Inc., she spent several years at Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School in various roles in the department of Neurology. Her most recent roles included Administrative Director of Inpatient Clinical Operations and Administrative Director for Education, with progressive responsibilities spanning resident and fellow recruitment, on-boarding, training and development, performance management, and program and project administration, among others. During her time in academia, Ms. Sagar was an invited member of the Education subcommittee at the American Academy of Neurology. Ms. Sagar holds a B.A. in Counseling from Dominion College and an M.P.A. from Suffolk University.

Rogerio Vivaldi, M.D., M.B.A
Rogerio Vivaldi, M.D., M.B.A President, Chief Executive Officer +
Leadership, Board of Directors

Rogerio Vivaldi Coelho, M.D., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018, and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme’s rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme’s Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro.

Daniel G. Anderson, Ph.D.
Daniel G. Anderson, Ph.D. +
Board of Directors, Founders, Scientific Advisory Board

Daniel G. Anderson, Ph.D., is a co-founder of Sigilon and has served as a member of our board of directors since 2016. Dr. Anderson is a leading researcher in the field of nanotherapeutics and
biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC.

Doug Cole, M.D.
Doug Cole, M.D. Chairman +
Board of Directors

Douglas Cole, M.D., has served as a member of our board of directors since 2015. Dr. Cole joined Flagship Pioneering, Inc., which conceives, creates, resources and develops first-in-category life sciences companies, in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Denali Therapeutics Inc. and a number of private companies. Previously, Dr. Cole served on the boards of directors of a number of public companies including Quanterix Corporation, Agios Pharmaceuticals Inc., Receptos, Inc., AVEO Pharmaceuticals Inc., Editas Medicine, Inc., Tetraphase Pharmaceuticals, Inc. and Concert Pharmaceuticals Inc. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his B.A. in English from Dartmouth College.

John Cox, M.B.A.
John Cox, M.B.A. Chief Executive Officer of Repertoire Immune Medicines +
Board of Directors

John Cox, M.B.A., has served as a member of our board of directors since 2019. Mr. Cox has served as the Chief Executive Officer of Repertoire Immune Medicines since 2019, and was formerly the Chief Executive Officer of Bioverativ Inc. from 2017 until 2019, which he built, grew, and led to a successful acquisition by Sanofi S.A. Previously, Mr. Cox was Executive Vice President, Global Commercial & Technical Operations at Biogen Inc. from 2016 until 2017, where he was a member of the leadership team and was globally responsible for all aspects of an $11 billion commercial operation, as well as technical development and all drug supply. Prior to that he served as Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc. from 2015 until 2016, in which capacity he oversaw the company’s production facilities, supply chain operations, technical development, quality and engineering across the globe. He also had responsibility for the creation of the company’s biosimilar business, including its successful commercialization in Europe. Mr. Cox holds an M.B.A. from the University of Michigan, an M.S. in cell biology from California State University and a B.S. in biology from Arizona State University.

Jim Gilbert, M.B.A.
Jim Gilbert, M.B.A. Director of Rubius Therapeutics +
Board of Directors

James Gilbert, M.B.A., has served as a member of our board of directors since June 2017. Mr. Gilbert is a senior partner of Flagship Pioneering. Before joining Flagship Pioneering, Inc. in 2016, Mr. Gilbert served as a senior advisor to the investment firm General Atlantic and as a senior operating executive at Welsh, Carson, Anderson & Stowe. From 2004-2010 Mr. Gilbert was an Executive Vice President of Corporate Strategy and BD, and Cardiovascular Group President at Boston Scientific Corporation and from 1981-2004 a Partner, including serving as the Managing Director of the Global Healthcare Practice and Chairman of the Management Committee at Bain & Company. In addition to our board, Mr. Gilbert is also a board member of National Dentex Corporation. He previously served on the boards of directors of ECG Management Consultants, Inc., KSQ Therapeutics, Inc., Kintai Therapeutics, Inc., Nestl´e Health Science S.A., Rubius Therapeutics, Inc. and TransMedics, Inc. Mr. Gilbert has a B.S. from Cornell University and an M.B.A. from Harvard Business School.

Robert Langer, Sc.D.
Robert Langer, Sc.D. +
Board of Directors, Founders, Scientific Advisory Board

Robert Langer, Sc.D., has served as a member of our board of directors since 2016. Since 2005, Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has served on the boards of directors of Abpro Corporation since 2016, Frequency Therapeutics, Inc. since 2016, Rubius Therapeutics, Inc. since 2014, Moderna, Inc. since 2010, and Lyra Therapeutics, Inc. since 2006. Dr. Langer has previously served on the boards of directors of Puretech Health plc, Momenta Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Kala Pharmaceuticals, Inc., Fibrocell Science, Inc., and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University.

Stephen Oesterle, M.D.
Stephen Oesterle, M.D. +
Board of Directors

Stephen Oesterle, M.D., has served as a member of our board of directors since 2016. Dr. Oesterle is a consultant, advising private equity and operating companies in the healthcare industry. From 2002 to 2015, he served as a member of the Executive Committee of Medtronic plc, a global medical technology, services and solutions company, and as Medtronic plc’s Senior Vice President, Medicine and Technology. Previously, he served as an Associate Professor of Medicine and Director of Invasive Cardiology Services at each of Massachusetts General Hospital from 1998 to 2002, Stanford University Medical Center from 1992 to 1998, and Georgetown University Medical Center from 1991 to 1992. Dr. Oesterle has served as a member of the board of directors of Baxter International Inc. since 2017 and Peijia Medical Limited since 2020. He served as a director of REVA Medical, Inc. from February 2018 to May 2019 and of HeartWare International, Inc. from January 2016 to November 2016, prior to Medtronic plc’s acquisition of HeartWare International, Inc.

Kavita Patel, M.D.
Kavita Patel, M.D. Nonresident Fellow at the Brookings Institution +
Board of Directors

Kavita Patel, M.D., has served as a member of our board of directors since 2020. Dr. Kavita Patel is a practicing physician in Washington, D.C., and a Nonresident Fellow at the Brookings Institution, where her research and reports focus on patient-centered care, payment and delivery systems and health reform. She previously served in the Obama Administration as Director of Policy for the Office of Intergovernmental Affairs and Public Engagement in the White House. She also served as a policy analyst and aide to the late Senator Edward Kennedy. As Deputy Staff Director on Health, she was part of the senior staff of the Health, Education, Labor and Pensions (HELP) Committee under Senator Kennedy’s leadership. Dr. Patel also served as the Managing Director of Clinical Transformation at the Center for Health Policy at the Brookings Institution and Vice President of Payer and Provider Strategy at Johns Hopkins Health System. Dr. Patel serves on the board of several non-profit organizations, including Dignity Healthcare and SSM Healthcare. She earned her M.D. from the University of Texas Health Science Center and her M.P.H. from the University of California, Los Angeles.

Robert Ruffolo, Jr., Ph.D.
Robert Ruffolo, Jr., Ph.D. +
Board of Directors

Robert R. Ruffolo, Jr., Ph.D., has served as a member of our board of directors since 2016. He served as the President of Research and Development and as the Corporate Senior Vice President of Wyeth Pharmaceuticals from 2000 through 2008. In these roles, he managed an R&D organization of 9,000 scientists with an annual budget in excess of $3 billion. From 2000 to 2002 he served as an Executive Vice President at Wyeth Pharmaceuticals, where he was responsible for Pharmaceutical Research and Development. Prior to joining Wyeth Pharmaceuticals, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals plc (now GlaxoSmithKline plc) where he was Senior Vice President and Director of Biological Sciences, Worldwide from 1984 to 2000. Before joining SmithKline Beecham Pharmaceuticals plc, Dr. Ruffolo spent six years at Eli Lilly and Company from 1978 to 1984 where he was a Senior Pharmacologist. Dr. Ruffolo currently serves on the boards of directors of Aridis Pharmaceuticals, Inc., Diffusion Pharmaceuticals, Inc. and several private companies. He received his B.S. in Pharmacy from The Ohio State University and his Ph.D. in Pharmacology from The Ohio State University.

Eric Shaff, M.B.A.
Eric Shaff, M.B.A. President and Chief Executive Officer of Seres Therapeutics +
Board of Directors

Eric Shaff, M.B.A., has served as a member of our board of directors since 2017. Mr. Shaff is President and Chief Executive Officer of Seres Therapeutics, Inc., a role that follows a series of leadership positions at Seres Therapeutics, Inc. beginning in 2015. Prior to Seres Therapeutics, Inc., Mr. Shaff worked at Momenta Pharmaceuticals, Inc. and Genzyme Corporation, where he served as global head of finance of Genzyme’s Rare Genetic Disease Division in addition to roles in corporate development and corporate Finance. Mr. Shaff has also worked in corporate finance at Pfizer Inc. and in investment banking with Broadview International LLC (now Jefferies Broadview). Mr. Shaff earned a B.A. from the University of Pennsylvania and holds an M.B.A. from the Johnson Graduate School of Management at Cornell University.

Daniel G. Anderson, Ph.D.
Daniel G. Anderson, Ph.D. +
Board of Directors, Founders, Scientific Advisory Board

Daniel G. Anderson, Ph.D., is a co-founder of Sigilon and has served as a member of our board of directors since 2016. Dr. Anderson is a leading researcher in the field of nanotherapeutics and
biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC.

Robert Langer, Sc.D.
Robert Langer, Sc.D. +
Board of Directors, Founders, Scientific Advisory Board

Robert Langer, Sc.D., has served as a member of our board of directors since 2016. Since 2005, Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has served on the boards of directors of Abpro Corporation since 2016, Frequency Therapeutics, Inc. since 2016, Rubius Therapeutics, Inc. since 2014, Moderna, Inc. since 2010, and Lyra Therapeutics, Inc. since 2006. Dr. Langer has previously served on the boards of directors of Puretech Health plc, Momenta Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Kala Pharmaceuticals, Inc., Fibrocell Science, Inc., and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University.

José Oberholzer, M.D.
José Oberholzer, M.D. +
Founders

José Oberholzer, M.D., is a scientific founder at Sigilon. He is a physician-scientist with a long track record in cell therapy. Dr. Oberholzer, brings a wealth of highly valuable islet encapsulation expertise to Sigilon. He is a researcher, surgeon and the director of the Charles O. Strickler Transplant Center at the University of Virginia. Previous to that he was a Professor of Surgery, Endocrinology and Diabetes, Bioengineering, and Chief of the Division of Transplantation at the University of Illinois at Chicago (UIC). Dr. Oberholzer graduated from the University of Zurich Medical School in Switzerland and obtained a master’s in health care management from Harvard University. He completed his surgical training at the University of Geneva (Switzerland), as well as at the University of Alberta in Edmonton (Canada), where he completed a fellowship in hepatobiliary and pancreatic surgery and transplantation. He was the Head of the Islet Transplant Program at the University of Geneva and the GRAGIL islet consortium from 1998 to 2002, completing a significant number of islet transplants. He has been heading UIC’s islet program since 2003.

Arturo Vegas, Ph.D.
Arturo Vegas, Ph.D. +
Founders

Arturo Vegas, Ph.D., Scientific Founder, provided fundamental contributions to the development of new materials for cell encapsulation and cell-based therapies as a post-doctoral fellow in the MIT laboratories of Robert Langer and Daniel G. Anderson. He is currently the Peter Paul Career Development Professor at Boston University. Appointed in the Department of Chemistry, Dr. Vegas has an affiliation with the Department of Biomedical Engineering and is a core faculty member of both the Boston University Center for Molecular Discovery as well as the Boston University Nanotechnology Innovation Center. Dr. Vegas received his B.A. from Cornell University and a Ph.D. in Chemistry from Harvard University. His work has led to 10 patents both issued and pending. He was recently awarded a New Innovator Type 1 Diabetes Pathfinder Award by the NIH.

Omid Veiseh, Ph.D.
Omid Veiseh, Ph.D. +
Founders

Omid Veiseh, Ph.D., Scientific Founder, has over a decade of experience developing biotechnologies for clinical application. The transformative research discoveries he made as a postdoctoral research fellow helped catalyze the launch of Sigilon. Through grants from the Juvenile Diabetes Research Foundation and the Department of Defense, Dr. Veiseh worked to develop a bioartificial pancreas for the treatment of patients afflicted with type 1 diabetes. Dr. Veiseh developed a high-throughput pipeline for the synthesis and evaluation of material formulations that are able to resist foreign body reactions. These formulations were used to develop novel biomaterials for enhanced biocompatibility. The results lay the groundwork for encapsulated transplanted cells for delivery of biotherapeutics. In 2017, he will join the faculty at Rice University as an Assistant Professor of Bioengineering. Dr. Veiseh holds a Ph.D. from the University of Washington. He has authored or co-authored more than 50 peer-reviewed publications and is an inventor on 20 pending or awarded patents.

Daniel G. Anderson, Ph.D.
Daniel G. Anderson, Ph.D. +
Board of Directors, Founders, Scientific Advisory Board

Daniel G. Anderson, Ph.D., is a co-founder of Sigilon and has served as a member of our board of directors since 2016. Dr. Anderson is a leading researcher in the field of nanotherapeutics and
biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC.

Constance Cepko, Ph.D.
Constance Cepko, Ph.D. +
Scientific Advisory Board

Constance Cepko, Ph.D., is Professor of Genetics and Neuroscience and Co-Director of the Leder Human Biology and Translational Medicine Program at Harvard Medical School. Her laboratory addresses questions regarding mechanisms of cell fate determination and has been developing gene therapy to address genetic forms of blindness. Dr. Cepko serves on the Scientific Advisory Boards of Permeon Biologics, Advanced Cell Technology and GenSight Biologics. Dr. Cepko is a member of American Academy of Arts and Sciences and member of the National Academy of Sciences.

Robert Langer, Sc.D.
Robert Langer, Sc.D. +
Board of Directors, Founders, Scientific Advisory Board

Robert Langer, Sc.D., has served as a member of our board of directors since 2016. Since 2005, Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has served on the boards of directors of Abpro Corporation since 2016, Frequency Therapeutics, Inc. since 2016, Rubius Therapeutics, Inc. since 2014, Moderna, Inc. since 2010, and Lyra Therapeutics, Inc. since 2006. Dr. Langer has previously served on the boards of directors of Puretech Health plc, Momenta Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Kala Pharmaceuticals, Inc., Fibrocell Science, Inc., and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University.

Ulrik B. Nielsen, Ph.D.
Ulrik B. Nielsen, Ph.D. Co-founder and CEO of Tidal Therapeutics +
Scientific Advisory Board

Ulrik B. Nielsen, Ph.D., is co-founder and CEO of Tidal Therapeutics, a company developing nucleotide-based therapeutics He was previously a co-founder, President and CEO of Torque Therapeutics from 2015 until 2018. Prior to Torque, Dr. Nielsen was co-founder and Chief Scientific Officer of Merrimack (NASDAQ: MACK) until 2015. Dr. Nielsen also serves on the Board of Directors for Alloy, Merrimack and North Therapeutics. He trained at the University of California, San Francisco, and MIT, and holds a Ph.D. in molecular biology from the University of Copenhagen.

Michael Rosenblatt, M.D.
Michael Rosenblatt, M.D. Chief Medical Officer of Flagship Pioneering +
Scientific Advisory Board

Michael Rosenblatt, M.D., serves as the Chief Medical Officer of Flagship Pioneering. Prior to this role, Dr. Rosenblatt was the Executive Vice President and Chief Medical Officer for Merck from 2009 until 2016. He also served as Dean of Tufts University School of Medicine, and held appointments as the Robert Ebert Professor of Molecular Medicine and then George R. Minot Professor of Medicine at Harvard Medical School. He was a scientific founder of ProScript, the company that discovered bortezomib (Velcade), now Millennium Pharmaceutical’s drug for multiple myeloma and other malignancies, and Radius Pharmaceuticals, a women’s health company. Dr. Rosenblatt is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. He serves as a member of the Board of Directors for Ferring Pharmaceuticals (U.S. Division), Rubius Therapeutics, Brooks Automation and several early stage biotech companies. Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency and endocrinology training were all at the Massachusetts General Hospital.

Bio

name

title